Trial Profile

A Double-blinded, Randomised, and Placebo-controlled Safety Study of AT-301 Nasal Spray in Healthy Adults

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AT-301 Atossa Therapeutics (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors Atossa Therapeutics

Most Recent Events

25 Feb 2021 Final results published in an Atossa Therapeutics Media Release.
10 Feb 2021 According to an Atossa Therapeutics media release, the company expects to release final data from this study in the first quarter of 2021.
14 Jan 2021 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com